Cyclacel(US:CYCC)2025-11-13 21:50Financial Performance - As of September 30, 2025, cash and cash equivalents totaled $3.8 million, an increase from $3.1 million as of December 31, 2024[4] - Product revenue from fire safety equipment sales was $81,000 for the three months ended September 30, 2025, compared to $0 for the same period in 2024[5][16] - Research and development expenses were $0 for the three months ended September 30, 2025, down from $1.0 million for the same period in 2024[7] - General and administrative expenses decreased to $1.0 million for the three months ended September 30, 2025, from $1.2 million in the same period in 2024[8] - The net loss for the three months ended September 30, 2025, was $1.0 million, compared to a net loss of $2.0 million for the same period in 2024[10][16] - Total assets increased to $8.16 million as of September 30, 2025, compared to $4.09 million as of December 31, 2024[18] Corporate Actions - Following the acquisition of Fitters Sdn. Bhd., the company now holds approximately 19.99% of all issued and outstanding shares of common stock of the Company[3] - The company entered into a Warrant Exchange Agreement in September 2025, exchanging existing warrants for an aggregate of 559,395 shares of common stock[3] - An Asset Purchase Agreement was signed in October 2025 to sell certain assets related to Plogosertib for a purchase price of $300,000, plus a potential milestone payment of $170,000[3] - The company declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock, paid on November 1, 2025[11]